Literature DB >> 20453014

Early changes on electroencephalography in natalizumab-associated progressive multifocal leucoencephalopathy.

Ingo Kleiter1, Michael Schröder, Ralf Lürding, Gerhard Schuierer, David B Clifford, Ulrich Bogdahn, Andreas Steinbrecher, Peter Pöschl.   

Abstract

Progressive multifocal leucoencephalopathy has become a growing concern in natalizumab-treated multiple sclerosis patients. Here, we describe a 35-year-old patient who was treated with 34 infusions of natalizumab before complaining about visual deterioration. MRI was non-diagnostic and JC virus testing initially was negative. Electroencephalography showed severe slowing of the right hemisphere, and neuropsychological testing revealed right frontal and temporal deficits. The diagnosis of progressive multifocal leucoencephalopathy was established 2 months later by typical MRI presentation and detection of JC virus DNA in the cerebrospinal fluid. Functional neurological deficits may precede imaging features and should prompt early consideration of progressive multifocal leucoencephalopathy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20453014     DOI: 10.1177/1352458510367718

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  5 in total

1.  Value of MRI as a surrogate marker for PML in natalizumab long-term therapy.

Authors:  I Ayzenberg; C Lukas; N Trampe; R Gold; K Hellwig
Journal:  J Neurol       Date:  2012-08       Impact factor: 4.849

2.  Prophylactic antiepileptic treatment reduces seizure frequency in natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Robert Hoepner; Stefanie Dahlhaus; Susanne Kollar; Barbara Zurawski; Andrew Chan; Ingo Kleiter; Ralf Gold; Kerstin Hellwig
Journal:  Ther Adv Neurol Disord       Date:  2014-01       Impact factor: 6.570

3.  Quantitative electroencephalography supports diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  G Classen; C Classen; C Bernasconi; C Brandt; R Gold; A Chan; R Hoepner
Journal:  J Neurovirol       Date:  2018-11-09       Impact factor: 2.643

Review 4.  Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis.

Authors:  Robert Hoepner; Simon Faissner; Anke Salmen; Ralf Gold; Andrew Chan
Journal:  J Cent Nerv Syst Dis       Date:  2014-04-28

5.  Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.

Authors:  Roderick P P W M Maas; Annemarie H G Muller-Hansma; Rianne A J Esselink; Jean-Luc Murk; Clemens Warnke; Joep Killestein; Mike P Wattjes
Journal:  J Neurol       Date:  2016-07-11       Impact factor: 4.849

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.